cystic
fibrosi
cf
rare
genet
condit
affect
peopl
worldwid
despit
implement
neonat
newborn
screen
program
countri
improv
patient
care
last
year
cfrelat
lung
diseas
remain
main
caus
morbiditymort
patient
role
bacteri
pathogen
staphylococcu
aureu
sa
pseudomona
aeruginosa
pa
extens
studi
sever
decad
wherea
respiratori
virus
pathogenesi
remain
littl
explor
avail
new
diagnost
molecular
test
detect
viru
infect
recent
boost
interest
evalu
impact
patholog
condit
cf
children
adult
howev
critic
lack
data
describ
viral
respiratori
tract
infect
rti
young
children
cf
age
less
year
rti
particularli
frequent
potenti
sever
earli
period
life
studi
conduct
late
drawn
pessimist
scenario
viral
rti
vulner
popul
longer
observ
semin
studi
clinic
manifest
describ
sever
frequent
requir
hospit
prolong
oxygen
suppli
mechan
ventil
patient
describ
acquir
pathogen
pa
week
month
follow
rti
time
respiratori
syncyti
viru
rsv
found
frequent
recov
viru
diagnost
tool
limit
immunolog
assay
viral
cultur
thu
limit
spectrum
viru
may
recov
recent
studi
shown
rsv
epidem
may
associ
occurr
pulmonari
exacerb
rsv
rare
respons
hospit
respiratori
event
cf
patient
design
prospect
cohort
studi
better
explor
frequenc
rti
along
sever
natur
viral
agent
recov
associ
shortterm
outcom
march
april
famili
contact
eight
refus
particip
three
repeat
nasal
swab
sampl
requir
two
overal
burden
studi
two
unexplain
reason
one
languag
barrier
issu
final
young
children
cf
age
less
month
recruit
particip
studi
confirm
cf
base
compat
clinic
featur
associ
two
posit
sweat
test
sweat
chlorid
concentr
mmoll
andor
two
cftr
gene
mutat
none
receiv
palivizumab
use
current
practic
prospect
cohort
studi
conduct
singl
pediatr
center
lyon
franc
studi
approv
local
institut
review
board
consultatif
de
protect
de
personn
dan
la
recherch
lyon
parent
legal
guardian
gave
assent
sign
inform
consent
form
children
enter
studi
primari
outcom
measur
frequenc
rti
per
year
secondari
outcom
measur
year
followup
viru
identif
multiplex
pcr
number
hospit
number
oralintraven
antibiot
cours
steroid
bronchodil
use
number
day
parent
work
absente
unschedul
outpati
visit
differ
weight
zscore
start
end
studi
comparison
virusneg
posit
rti
age
weight
zscore
inclus
differ
weight
zscore
begin
end
studi
period
total
number
rti
cumul
number
day
antibiot
percentag
sampl
posit
pa
sa
total
number
sampl
taken
routin
studi
new
isol
pathogen
routin
practic
franc
chest
physiotherapist
visit
patient
home
ensur
regular
chest
physiotherapi
respiratori
surveil
alreadi
report
thought
proper
nasal
sampl
fill
diari
parent
may
difficult
perform
repeatedli
long
period
time
chest
physiotherapist
therefor
involv
studi
take
nasal
sampl
recogn
rti
parent
chest
physiotherapist
instruct
recogn
rti
use
modifi
clinic
score
alreadi
use
previou
studi
conduct
van
ewijk
al
young
children
cf
score
systemat
perform
twice
weekli
parent
studi
use
request
parent
physiotherapist
detect
confirm
possibl
rti
episod
reveal
occurr
symptom
briefli
upper
lower
respiratori
tract
infect
urti
lrti
symptom
well
gener
sign
fever
record
score
calcul
case
doubt
parent
could
ask
research
nurs
phone
chest
physiotherapist
home
visit
confirm
find
score
nasal
sampl
collect
home
chest
physiotherapist
within
maximum
day
begin
symptom
center
episod
coincid
visit
furthermor
nasal
swab
systemat
schedul
even
absenc
rti
sign
follow
frequenc
depend
viral
season
everi
month
septemb
march
everi
month
april
octob
year
follow
inclus
studi
nasopharyng
sampl
taken
accord
recent
describ
procedur
use
swab
compliant
mwe
corsham
wiltshir
uk
salin
instil
respiratori
specimen
sampl
pharyng
swab
bacteri
cultur
perform
center
visit
four
six
sampl
per
patient
per
year
depend
age
inclus
bacteri
cultur
perform
specif
media
order
identifi
major
cf
pathogen
sa
pa
coloni
morpholog
gram
stain
use
first
identif
bacteri
speci
malditofm
approach
done
final
identif
ten
pathogen
test
combin
five
duplex
rtpcr
pcr
influenza
b
respiratori
syncyti
viru
rsv
metapneumoviru
mpv
rhinovirusenteroviru
rvev
coronaviru
parainfluenza
viru
adenoviru
bocaviru
respiratori
multiwel
system
mw
marci
l
franc
cycl
threshold
ct
report
posit
sampl
consid
posit
valu
quantit
variabl
report
mean
standard
deviat
quantit
variabl
compar
use
nonparametr
statist
test
wilcoxon
sign
rank
pair
comparison
pearson
correl
coeffici
r
use
assess
relationship
two
variabl
statist
analys
perform
use
sa
sa
institut
cari
nc
usa
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
signific
level
set
twentyf
young
children
mean
age
month
rang
month
includ
tabl
half
sibl
immedi
famili
environ
half
attend
exclus
famili
daycar
none
receiv
palivizumab
patient
vaccin
influenza
viru
sixti
percent
commens
flora
inclus
eightyf
rti
identifi
averag
rti
per
child
per
year
viral
proven
rti
identifi
averag
per
child
per
year
correl
age
inclus
total
number
rti
pearson
correl
r
p
virusposit
rti
pearson
correl
r
p
fig
correl
age
inclus
total
respiratori
tract
infect
b
viru
posit
respiratori
tract
infect
episod
specif
clinic
featur
relat
viralposit
rti
year
followup
sampl
collect
home
visit
center
mean
sampl
per
patient
rti
clinic
identifi
sampl
collect
symptom
occurr
sampl
realiz
rti
sampl
associ
identif
viral
agent
fig
flow
chart
viru
sampl
result
virus
recov
viral
rti
rvev
rsv
adenoviru
influenza
bocaviru
parainfluenza
metapneumoviru
eight
viral
coinfect
identifi
rti
one
requir
hospit
tabl
six
patient
present
rsv
infect
clinic
progress
uncompl
tabl
onethird
viral
sampl
collect
outsid
rti
episod
virusposit
tabl
compar
recov
rti
proport
quit
similar
rv
adenovirus
metapneumoviru
howev
smaller
proport
rsv
influenza
higher
proport
bocaviru
coronaviru
found
nasal
swab
collect
outsid
rti
period
differ
found
virusposit
neg
rti
among
follow
outcom
measur
age
inclus
weight
zscore
inclus
differ
weight
zscore
begin
end
studi
period
total
number
rti
cumul
number
day
antibiot
one
hospit
directli
relat
viral
rti
lrti
relat
coinfect
five
hospit
other
caus
hospit
nonrespiratori
viral
infect
gastroenter
two
case
one
prolong
cardiorespiratori
monitor
one
surgeri
hexadactylia
supplement
medic
need
vast
major
viral
rti
oral
antibiot
prescrib
least
patient
mean
length
day
mean
cumul
number
day
day
oral
steroid
use
five
patient
mean
length
day
prolong
recurr
wheez
spell
bronchodil
use
four
mean
length
day
signific
correl
found
total
number
rti
viral
proven
cumul
number
day
antibiot
use
year
followup
pearson
correl
r
p
viral
rti
associ
mean
day
parent
absente
begin
studi
mean
weight
zscore
end
studi
correl
weight
zscore
differ
start
end
studi
number
viral
rti
occur
year
pearson
correl
r
p
four
percent
patient
posit
pa
sa
inclus
mean
swab
taken
schedul
visit
center
bacteri
analysi
studi
new
isol
pa
occur
five
patient
ten
patient
sa
noteworthi
none
particip
stenotrophomona
maltophilia
sm
inclus
four
acquir
bacterium
studi
period
small
number
patient
subgroup
preclud
statist
analysi
howev
trend
higher
number
total
rti
patient
new
isol
pa
notic
sm
tabl
recent
data
describ
rti
frequenc
clinic
consequ
natur
viru
recov
young
patient
year
cf
use
molecular
diagnost
tool
consortium
set
usa
australia
precis
evalu
impact
earli
respiratori
viral
infect
young
children
cf
found
mean
rti
episod
occur
patient
year
maximum
number
rti
record
seven
one
patient
frequenc
accord
data
report
collinson
et
al
late
urti
per
year
children
year
age
use
cultur
serolog
tool
half
episod
identifi
use
pcr
winter
month
report
van
ewijk
et
al
popul
children
cf
mean
year
old
recent
data
publish
swiss
group
provid
precis
rti
frequenc
calcul
methodolog
differ
reason
lrti
frequenc
report
studi
like
stem
score
system
way
use
purpos
studi
socal
respiratori
ill
score
system
develop
van
ewijk
et
al
parent
selfrecord
urti
andor
lrti
clinic
symptom
clinic
score
systemat
measur
twice
weekli
present
studi
high
risk
error
fill
diari
give
longer
period
time
month
vs
van
ewijk
et
al
studi
chose
use
systemat
basi
rather
aid
parent
home
caregiv
detect
rti
launch
nasal
sampl
furthermor
appear
rti
episod
may
miss
use
score
particularli
mild
urti
expect
young
popul
rvev
remain
frequent
recov
virus
rti
sinc
spread
molecular
diagnost
tool
mani
studi
report
result
older
children
adolesc
adult
overal
rvev
respons
viral
induc
rti
howev
intrigu
rsv
infect
detect
six
patient
infect
rsv
mean
age
month
none
requir
hospit
even
youngest
patient
clinic
cours
uncompl
find
contrast
report
decad
ago
unscreen
cf
babi
rsv
infect
describ
sever
requir
oxygen
suppli
invas
ventil
three
seven
patient
overal
better
health
statu
children
cf
present
sampl
like
main
explan
result
well
older
age
time
rsv
infect
result
particularli
interest
term
rsv
infect
prevent
subsequ
clinic
trial
popul
patient
palivizumabfre
american
academi
pediatr
recommend
use
palivizumab
cf
target
patient
particularli
poor
nutrit
statu
sever
sibl
specul
precaut
prevent
measur
hand
wash
famili
daycar
attend
avoid
viral
infect
individu
etc
follow
parent
medic
advic
initi
may
effici
enough
reduc
viru
circul
around
patient
approxim
onethird
studi
popul
carri
virus
without
symptom
rvev
recov
case
clinic
signific
find
current
unknown
underli
mechan
potenti
consequ
whether
subtyp
picornaviru
rv
ev
address
studi
prolong
carriag
report
recent
studi
conduct
mean
year
old
rang
year
cf
patient
popul
sampl
weekli
month
author
found
patient
cf
frequent
prolong
carriag
rv
comparison
healthi
counterpart
even
subtyp
differ
author
conclud
may
indic
increas
viral
replic
andor
decreas
viral
antivir
defens
patient
cf
younger
patient
includ
within
first
month
life
korten
et
al
found
rv
without
symptom
detect
case
viru
detect
less
frequent
associ
symptom
comparison
healthi
infant
rais
question
pathogen
virus
young
patient
cf
found
trend
toward
higher
frequenc
total
rti
young
children
first
isol
pa
sm
occur
year
followup
howev
find
trend
sa
howev
studi
power
specif
address
question
thu
prevent
us
draw
firm
conclus
risk
factor
rti
repres
pa
colon
underlin
sever
year
ago
particularli
sever
episod
rti
furthermor
major
pathogen
acquisit
young
children
cf
pa
sa
achromobact
xylosoxidan
may
follow
season
underpin
concept
predispos
season
environment
factor
respiratori
viru
epidem
howev
trend
identifi
herein
sm
seem
somewhat
new
need
attent
whether
virus
abl
directli
alter
airway
bacteri
flora
young
patient
cf
alter
relat
frequent
usag
antibiot
remain
determin
studi
strength
includ
prospect
cohort
design
one
first
studi
conduct
young
children
palivizumabfre
cf
prevent
potenti
interfer
monoclon
antibodi
respiratori
viral
epidemiolog
home
sampl
taken
physiotherapist
use
detail
protocol
ensur
collect
goodqual
sampl
studi
also
limit
fewer
sampl
comparison
recent
studi
hand
despit
presenc
healthcar
provid
home
score
system
use
help
parent
profession
caregiv
identifi
rit
children
weak
may
miss
sever
mild
rti
overal
low
number
sampl
subgroup
make
analysi
wellknown
risk
factor
rti
daycar
attend
tobacco
smoke
exposur
imposs
subject
median
age
inclus
month
like
alreadi
late
evalu
clinic
impact
viral
rti
known
worrisom
youngest
age
usual
month
age
final
healthi
control
includ
comparison
purpos
studi
show
respiratori
virus
respons
around
twothird
rti
young
children
cf
contrast
older
studi
accord
recent
studi
viral
rti
usual
mild
sever
except
lead
hospit
rsv
infect
rare
rais
question
use
rsv
prevent
medic
young
popul
